In bladder cancer specimens, loss of immunoreactivity for GULP1 was more frequently seen in muscle-invasive tumors (85.8%) than in non-muscle-invasive tumors (39.0%) [29]. This evidence concerns the gene GULP1 and urinary bladder carcinoma.